Bessemer Group’s Prelude Therapeutics PRLD Stock Holding History

Bessemer Group’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-89	Closed	-$1K	–	2329
2023 Q1	$1K	Hold	89	–	–	﹤0.01%	1874
2022 Q4	$1K	Buy	+89	New	+$570	﹤0.01%	1824

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Bessemer Group's PRLD Position: Q2 2023 in Review

Bessemer Group sold out of Prelude Therapeutics (PRLD) in Q2 2023, closing a stake of 89 shares — an estimated $1K sold.

Bessemer Group first reported a position in PRLD in Q4 2022 and held it in 2 quarters. The position peaked at $1K in Q1 2023. 55 funds tracked by Wall St. Rank hold PRLD as of Q2 2023.

Bessemer Group reported no remaining Prelude Therapeutics position as of Q2 2023 after selling out during the quarter.
Bessemer Group sold 89 Prelude Therapeutics shares in Q2 2023, an estimated $1K.
Bessemer Group first reported a position in Prelude Therapeutics in Q4 2022 and held it in 2 quarters.
Bessemer Group's Prelude Therapeutics position peaked at $1K in Q1 2023.
55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2023.

Based on Bessemer Group's 13F filing for Q2 2023, filed 10 Aug 2023.